Rheumatoid Arthritis

A Mendelian randomization analysis provided new insights into the relationship between inflammatory cytokines and ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis.

A Finnish study finds elevated cardiovascular risk in rheumatic diseases peaks within a year of diagnosis, emphasizing the need for early management strategies.

In a new study, cross-sectional analyses showed each 1-year increase in age-adjusted biological age was linked to a 1% - 10% increase in the risk of rheumatoid arthritis.

Patients with ACPA-positive RA and obesity had greater DAS44 scores compared to normal-weight patients, although this difference was not present in ACPA-negative RA.

Patients with both rheumatoid arthritis and depression have an increased risk of mortality by more than 2 times than patients with RA but no depression, according to a new study.

Results call attention to the potential for early intervention and risk stratification for developing RA based on remnant cholesterol.

Patients with rheumatoid arthritis who received acupuncture had a lower cumulative incidence of ischemic stroke compared to those who did not.

Multivariable analyses found genetic predispositions to overall rheumatoid arthritis with decreased sleep duration, as well as a significant genetic association between seropositive rheumatoid arthritis and insomnia symptoms.

Results demonstrated IHL-675A was well-tolerated, with no concerning adverse events or serious adverse events reported.

Patients with rheumatic disease treated with biosimilar SDZ ETN reported high treatment persistence at month 12 as well as comparable safety and efficacy.

Promising results of the phase 2 and 3 trials offer hope for patients with chronic and debilitating autoantibody-driven diseases.

Four themes emerged from the data, including the positive impact of exercise on sleep, positive experiences of the exercise intervention, mental health benefits, and achieving empowerment and ownership during the exercise process.

The 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis provides updated recommendations for the pharmacologic management of RA. In honor of Rheumatoid Arthritis Awareness Day, test your knowledge with this quiz:

Patients with inflammatory arthritis demonstrated significantly increased odds of depression and anxiety health care encounters and use of anxiolytics and antidepressants.

The presence of mental health, pain-related illnesses, and metabolic diseases were significantly associated with the worsening of arthritis-related pain, severity, and disease activity.

Angus Worthing, MD, discusses the recent developments in rheumatology and his predictions for the future of treatment moving into 2024 and beyond.

In a study involving over 500 children, artificial intelligence using echocardiography demonstrated accuracy comparable to expert cardiologists in detecting rheumatic heart disease, hinting at the prospect of a potentially transformative tool for early intervention and disease prevention.

How well do patients with rheumatoid arthritis adhere to treatment with a TNF inhibitor and how likely and long lasting is remission? Test your knowledge with this quiz.

Wesley Mizutani, MD, discusses California's SB 496 legislation, which addresses the crucial role of biomarkers in guiding optimal drug selection to improve overall healthcare outcomes.

Improvements in insulin resistance were reported in patients with RA and type 2 diabetes treated with tofacitinib.

As gastrointestinal (GI) symptoms are common in the US, how does rheumatoid arthritis (RA) affect the frequency of GI events? Test your knowledge with this quiz.

Entering menopause prior to age 45 was associated with a 46% increased risk of developing RA compared with those who began menopause at ≥50 years.

Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.

Results indicated patients with GERD are at a 69% increased risk of developing RA.

Laura Donlin, PhD, highlights the significance of identifying new subtypes of rheumatoid arthritis, emphasizing the potential for a paradigm shift in RA treatment toward personalized care and early interventions.

Peter C Taylor, PhD, discusses the efficacy and safety of nipocalimab in patients with active rheumatoid arthritis.

Expert rheumatologists discuss precision medicine in rheumatoid arthritis. In particular, they discuss available data and the value of various tools in guiding treatment selection in routine clinical practice.

In these phase 3 findings presented at ACR 2023, the safety and efficacy of this drug was proven in ACR20, ACR50, and DAS28-ESR responses.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.